Global Myocarditis Disease Market – Industry Trends and Forecast to 2029

Análisis y tamaño del mercado

En los últimos años, se prevé que el mercado de la enfermedad de miocarditis crezca rápidamente durante el período de pronóstico. La miocarditis es una enfermedad en la que el músculo cardíaco (miocardio) se inflama. Para bombear sangre dentro y fuera del corazón y por todo el cuerpo, este músculo se contrae y se relaja. Puede producir coágulos de sangre, que pueden provocar un ataque cardíaco o un derrame cerebral, daño cardíaco o la muerte en circunstancias extremas. Debido a que no se puede utilizar ninguna prueba ampliamente disponible a nivel de población, la investigación basada en la población no puede determinar la incidencia y la prevalencia de la miocarditis. En 2010, casi 400.000 personas murieron en todo el mundo por enfermedad del músculo cardíaco (miocardiopatía, que incluye la miocarditis), y murieron 160.000 mujeres y 240.000 hombres.

Data Bridge Market Research analiza que el mercado de la enfermedad de miocarditis se valoró en USD 1.592 mil millones en 2021 y se espera que alcance los USD 2.57 mil millones para 2029, registrando una CAGR del 6,15% durante el período de pronóstico de 2022 a 2029. El informe de mercado curado por el equipo de Data Bridge Market Research incluye un análisis experto en profundidad, epidemiología del paciente, análisis de la cartera, análisis de precios y marco regulatorio.

Definición de mercado

Cuando el músculo cardíaco (miocardio) se inflama, se produce una miocarditis. La inflamación se produce cuando el sistema inmunitario, por ejemplo, responde a infecciones. Las infecciones víricas o enfermedades inflamatorias más sistémicas, como los trastornos autoinmunes, pueden provocar miocarditis. En los casos graves de miocarditis, el músculo cardíaco se debilita y no puede bombear sangre adecuadamente a otras regiones del cuerpo.

Alcance del informe y segmentación del mercado

Dinámica del mercado de la enfermedad de la miocarditis

Conductores

• Aumento de la prevalencia de trastornos crónicos

Se estima que la creciente prevalencia de enfermedades crónicas impulsará el crecimiento del mercado. Las enfermedades crónicas como la diabetes, el VIH/SIDA, el cáncer y otras son los factores de riesgo que conducen a la aparición de la enfermedad de miocarditis, por lo que influyen en la dinámica del mercado durante el período de pronóstico de 2022 a 2029.

• Aumentar la inversión en infraestructura sanitaria

Otro factor importante que influye en la tasa de crecimiento del mercado de la enfermedad de miocarditis es el aumento del gasto sanitario, que ayuda a mejorar su infraestructura. Además, varias organizaciones gubernamentales tienen como objetivo mejorar la infraestructura sanitaria aumentando la financiación, lo que influirá aún más en la dinámica del mercado.

• Creciente número de población geriátrica

Se estima que el aumento de la población geriátrica impulsará la expansión del mercado durante el período de pronóstico de 2022 a 2029. Según la Organización Mundial de la Salud (OMS), se espera que la población geriátrica mundial, que se estimó en más de 524 millones en 2010, aumente a casi 2 mil millones para 2050. Debido a sus sistemas inmunológicos comprometidos, los geriátricos son más susceptibles a contraer enfermedades cardiovasculares, lo que se estima que impulsará aún más la tasa de crecimiento del mercado.

Además, las crecientes iniciativas de organizaciones públicas y privadas para difundir la información ampliarán el mercado de la enfermedad de la miocarditis. Además, el cambio en el estilo de vida de las personas y el aumento del consumo de diversos medicamentos, incluidos los antibióticos, como la penicilina y las sulfonamidas, y algunos medicamentos anticonvulsivos, darán lugar a la expansión del mercado de la enfermedad de la miocarditis.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the myocarditis disease market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate. 

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the myocarditis disease market growth during the forecast period.

Restraints/Challenges

On the other hand, high cost associated with the treatment will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the myocarditis disease market. Additionally, strict regulatory policies and lack of awareness among people will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This myocarditis disease market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the myocarditis disease market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Myocarditis disease market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Myocarditis Disease Market

Since its emergence in December 2019, the COVID-19  virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in the pneumonia cases. This virus spread quickly over the world, killing a large number of people. COVID-19 was labelled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in a number of nations had imposed nationwide lockdowns in order to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world were having difficulty continuing their supply chain activities. The myocarditis disease market was hampered by the supply chain slowness.

Global Myocarditis Disease Market Scope

The myocarditis disease market is segmented on the basis of type, treatment, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Acute Myocarditis
• Chronic Myocarditis
• Lymphocytic Myocarditis

Diagnosis

• Blood Tests
• Cardiac Catheterization
• Heart Muscle Biopsy
• Imaging Tests
• Echocardiogram
• Chest X-ray
• Electrocardiogram (ECG)
• Magnetic resonance imaging (MRI)
• Others
• Treatment
• Medication
• Diuretics
• Beta blockers
• Angiotensin-converting enzyme (ACE) inhibitors
• Corticosteroids
• Others
• Surgery
• Heart transplant
• Extracorporeal membrane oxygenation (ECMO)
• Intra-aortic balloon pump
• Ventricular assist devices (VAD)
• IV medications
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Myocarditis Disease Market Regional Analysis/Insights

The myocarditis disease market is analysed and market size insights and trends are provided by country, type, treatment, diagnosis, route of administration, end-users and distribution channel as referenced above.

The countries covered in the myocarditis disease market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the myocarditis disease market because of the rising number of research activities in this region. Additionally, rising healthcare expenditure and presence of major key players will further propel the market’s growth rate in this region.

Asia-Pacific are expected to grow during the forecast period due to increasing cases of cardiovascular diseases in this region. Also, development of healthcare infrastructure and rising geriatric population will further propel the market’s growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Myocarditis Disease Market Share Analysis

The myocarditis disease market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to myocarditis disease market.

Some of the major players operating in the myocarditis disease market are:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (US)
• Teva Pharmaceutical Industries Ltd.(Israel)
• Sanofi (France)
• Pfizer Inc. (US)
• GlaxoSmithKline plc (UK)
• Novartis AG (Switzerland)
• Zydus Cadila (India)
• AstraZeneca (UK)
• Johnson & Johnson (US)
• Bayer AG (Germany)
• Sun Pharmaceutical Industries Ltd. (India)
• Bristol-Myers Squibb Company (US)
• Eli Lilly and Company (US)
• Cipla Inc. (US)
• Aurobindo Pharma (India)
• Lupin (India)
• AbbVie Inc. (US)
• LEO Pharma A/S (Denmark)

SKU-54483